Vivos Therapeutics (VVOS) FCF Margin (2020 - 2026)
Vivos Therapeutics (VVOS) reported FCF Margin of 117.25% for Q1 2026, up 1265.0% year-over-year from 8.59% in Q1 2025, and up 44.9% quarter-over-quarter from 212.81% in Q4 2025.
Vivos Therapeutics (VVOS) FCF Margin (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of FCF Margin data on file, last reported at 117.25% in Q1 2026.
- FCF Margin for Q1 2026 came in at 117.25%, up 1265.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 115.28% (down 1609.0% YoY), and the FY2025 annual result was 117.23%, down 2902.0% from the prior year.
- FCF Margin improved to 117.25% in Q1 2026 per VVOS's latest filing, from 212.81% in the prior quarter.
- Over five years, FCF Margin peaked at 60.7% in Q3 2025 and troughed at 212.81% in Q4 2025.
- A 5-year average of 108.48% and a median of 98.2% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2025: FCF Margin surged 7865 bps in 2023, then sank 12885 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 80.68% in 2022, then climbed by 19 bps to 65.02% in 2023, then slipped by 29 bps to 83.96% in 2024, then sank by 153 bps to 212.81% in 2025, then surged by 45 bps to 117.25% in 2026.
- Business Quant data shows VVOS's FCF Margin at 117.25% in Q1 2026, 212.81% in Q4 2025, and 60.7% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 25.51% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -1.28% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.68% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 37.67% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 3.98% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 15.44% |
| 10 | Vivos Therapeutics | 7.39 Mn | 5.16 Mn | 3.06 Mn | -117.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.25% |
| Dec 31, 2025 | -212.81% |
| Sep 30, 2025 | -60.70% |
| Jun 30, 2025 | -111.91% |
| Mar 31, 2025 | -129.91% |
| Dec 31, 2024 | -83.96% |
| Sep 30, 2024 | -113.45% |
| Jun 30, 2024 | -76.67% |
| Mar 31, 2024 | -78.01% |
| Dec 31, 2023 | -65.02% |
| Sep 30, 2023 | -89.49% |
| Jun 30, 2023 | -98.20% |
| Mar 31, 2023 | -92.04% |
| Dec 31, 2022 | -80.68% |
| Sep 30, 2022 | -141.31% |
| Jun 30, 2022 | -121.99% |
| Mar 31, 2022 | -170.69% |
| Dec 31, 2021 | -50.48% |
| Sep 30, 2021 | -97.98% |
| Jun 30, 2021 | -111.43% |